We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+18.8%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.68B
AUM Growth
+$421M
Cap. Flow
+$308M
Cap. Flow %
11.53%
Top 10 Hldgs %
68.02%
Holding
83
New
12
Increased
16
Reduced
6
Closed
11
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
0.7 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$68.6M
2
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$52.4M
3
RLAY icon
Relay Therapeutics
RLAY
+$34.9M
4
RCUS icon
Arcus Biosciences
RCUS
+$32.5M
5
JANX icon
Janux Therapeutics
JANX
+$31.4M

Top Sells

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$11.9M
2
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$10.5M
3
NGNE icon
Neurogene
NGNE
+$8.45M
4
ACIU icon
AC Immune
ACIU
+$6.91M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 98.93%
2 Financials 0.6%
3 Miscellaneous 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
OVID icon
26
Ovid Therapeutics
OVID
$441M
$23.8M 0.89%
6,082,200
– –
2021 Q1
1 quarter
NGNE icon
27
Neurogene
NGNE
$479M
$21.8M 0.81%
117,940
-38,195
-24% -$8.45M
2018 Q2
12 quarters
ACIU icon
28
AC Immune
ACIU
$244M
$21M 0.78%
2,648,163
-1,000,000
-27% -$6.91M
2020 Q4
2 quarters
BCEL
29
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$20.7M 0.77%
2,426,685
– –
2019 Q2
8 quarters
CNTA
30
DELISTED
Centessa Pharmaceuticals
CNTA
$16.8M 0.63%
+754,545
New +$17.7M
2021 Q2
0 quarters
KDNY
31
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$13.2M 0.49%
931,650
-318,351
-25% -$5.09M
2020 Q4
2 quarters
ZNTL icon
32
Zentalis Pharmaceuticals
ZNTL
$212M
$10.6M 0.4%
+200,000
New +$10.7M
2021 Q2
0 quarters
CRVS icon
33
Corvus Pharmaceuticals
CRVS
$829M
$9.56M 0.36%
+3,579,377
New +$9.85M
2021 Q2
0 quarters
KRON icon
34
DELISTED
Kronos Bio
KRON
$9.28M 0.35%
387,357
– –
2020 Q4
2 quarters
TNGX icon
35
Tango Therapeutics
TNGX
$3.83B
$9.1M 0.34%
800,000
– –
2020 Q3
3 quarters
NUVB.WS icon
36
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.97M 0.34%
963,333
– –
2021 Q1
1 quarter
KLRS icon
37
Kalaris Therapeutics
KLRS
$52.1M
$8.82M 0.33%
19,435
– –
2020 Q3
3 quarters
CCCC icon
38
C4 Therapeutics
CCCC
$342M
$7.57M 0.28%
200,000
– –
2020 Q4
2 quarters
KRSA
39
Korsana Biosciences, Inc. Common Stock
KRSA
$1.53B
$6.26M 0.23%
11,473
– –
2019 Q2
8 quarters
VERV icon
40
DELISTED
Verve Therapeutics
VERV
$6.03M 0.23%
+100,000
New +$4.15M
2021 Q2
0 quarters
SYRS icon
41
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.45M 0.2%
100,000
– –
2020 Q4
2 quarters
JYAC
42
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.97M 0.19%
500,000
– –
2020 Q4
2 quarters
ALPN icon
43
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.7M 0.18%
522,635
-218,655
-29% -$2.38M
2020 Q3
3 quarters
DYN icon
44
Dyne Therapeutics
DYN
$2.86B
$4.52M 0.17%
215,000
– –
2020 Q3
3 quarters
OBIO icon
45
Orchestra BioMed
OBIO
$345M
$4.08M 0.15%
400,000
– –
2020 Q3
3 quarters
DNTH icon
46
Dianthus Therapeutics
DNTH
$4.17B
$3.59M 0.13%
22,929
-11,843
-34% -$2.18M
2021 Q1
1 quarter
IGMS icon
47
DELISTED
IGM Biosciences
IGMS
$3.16M 0.12%
+38,030
New +$2.82M
2021 Q2
0 quarters
ODT
48
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$2.9M 0.11%
+831,200
New +$2.85M
2021 Q2
0 quarters
NGM
49
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.83M 0.11%
143,567
– –
2020 Q4
2 quarters
FMTX
50
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$2.63M 0.1%
+105,638
New +$2.84M
2021 Q2
0 quarters
1
2
3 4

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2021 Portfolio in Review

As of Q2 2021, EcoR1 Capital held 83 positions worth $2.68B, up 19% from $2.25B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $308M of net new capital in Q2 2021, opening 12 new positions and adding to 16 existing holdings. Its largest new stake was Janux Therapeutics: 1,411,975 shares worth $35.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Neurogene, an estimated $8.45M trimmed.

  • EcoR1 Capital's largest Q2 2021 buy was Janux Therapeutics: 1,411,975 shares worth $35.2M.
  • EcoR1 Capital added most to Alector in Q2 2021, an estimated $68.6M increase.
  • EcoR1 Capital's biggest Q2 2021 reduction was Neurogene, cutting an estimated $8.45M.
  • EcoR1 Capital fully exited Eledon Pharmaceuticals in Q2 2021, selling an estimated $11.9M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.68B portfolio in Q2 2021.
  • EcoR1 Capital opened 12 new positions and closed 11 in Q2 2021.
  • EcoR1 Capital's portfolio value rose 19% quarter-over-quarter to $2.68B.

Based on EcoR1 Capital's 13F filing for Q2 2021, filed 16 Aug 2021.